COVID-19

[Signal Transduction and Targeted Therapy] The authors summarize the results of single-cell sequencing of peripheral blood, lung tissue, and cerebrospinal fluid of COVID-19 patients and describe the differentiation trajectory of myeloid cells in patients.

[Science] Investigators reported the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles.

[Science Immunology] Researchers monitored T cell responses to the Spike protein of SARS-CoV-2 in 71 healthy donors vaccinated with two doses of the Pfizer–BioNTech mRNA vaccine for up to six months after vaccination.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers found that, in contrast to current convention, “immunodominant” SARS-CoV-2 peptides defined by in silico methods often failed to elicit T cell responses recognizing naturally presented SARS-CoV-2 epitopes.

[Scientific Reports] The authors assessed concentrations of chemerin, omentin, and vaspin among COVID-19 patients with an emphasis on adipokines relationship with COVID-19 severity, concomitant metabolic abnormalities and liver dysfunction.

[Annals of Neurology] Cerebrospinal fluid was assessed between day 1-30, between day 31-90, or later than 90 days of COVID-19 diagnosis.